Biodesix Announces Third Quarter 2023 Results and Highlights
Biodesix Inc. announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update.
×
254 Results
Biodesix Inc. announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update.
Biodesix, Inc. is proud to announce that its CFO, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors.
Biodesix announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7.
Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update.
Discover key insights from Biodesix at CHEST 2023 on Nodify Lung® tests, impacting pulmonary nodule management and reducing invasive procedures.
Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023.
Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference.
Biodesix announced Scott Hutton, CEO, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference
Biodesix announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing.
Biodesix announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures.
Biodesix presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules.
Biodesix announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7.
Biodesix reveals key NSCLC proteomic test data at IASLC 2023, highlighting VeriStrat's predictive power and the Risk of Recurrence test's precision
Biodesix reveals ORACLE study results: Nodify XL2 test effectively identifies benign lung nodules, leading to a 51% increase in lung cancer diagnosis rates and fewer invasive procedures.
Biodesix Q2 2023: Core Lung Diagnostic revenue at $11.4M (up 58% YoY), 73% profit margin. 2023 guidance: $52-55M. $27.5M private shares sold.
Biodesix CEO to present at Canaccord Genuity's 43rd Annual Growth Conference on Aug 9, 2023. Discover data-driven lung disease solutions at Biodesix.com.
Biodesix announces the designation of its Nodify CDT Test as an Advanced Diagnostic Laboratory Test by CMS, recognizing its innovation and clinical value in assessing the risk of malignancy in pulmonary nodules
INSIGHT study monitors 5,000 NSCLC patients for 3 years, validating VeriStrat® test. Biodesix: leading lung disease diagnostic solutions.
Biodesix reports Q1 2023 results: 86% increase in Core Lung Diagnostic revenue, record test numbers, and reaffirms 2023 financial outlook.
three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR)
Biodesix announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.
Biodesix announces its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.
Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person investor meetings at Cowen’s 43rd Annual Healthcare Conference.